These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 22170739)

  • 1. Aberrantly methylated PKP1 in the progression of Barrett's esophagus to esophageal adenocarcinoma.
    Kaz AM; Luo Y; Dzieciatkowski S; Chak A; Willis JE; Upton MP; Leidner RS; Grady WM
    Genes Chromosomes Cancer; 2012 Apr; 51(4):384-93. PubMed ID: 22170739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression.
    Jin Z; Hamilton JP; Yang J; Mori Y; Olaru A; Sato F; Ito T; Kan T; Cheng Y; Paun B; David S; Beer DG; Agarwal R; Abraham JM; Meltzer SJ
    Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):111-7. PubMed ID: 18199717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus.
    Zou H; Molina JR; Harrington JJ; Osborn NK; Klatt KK; Romero Y; Burgart LJ; Ahlquist DA
    Int J Cancer; 2005 Sep; 116(4):584-91. PubMed ID: 15825175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alterations of the Wnt signaling pathway during the neoplastic progression of Barrett's esophagus.
    Clément G; Braunschweig R; Pasquier N; Bosman FT; Benhattar J
    Oncogene; 2006 May; 25(21):3084-92. PubMed ID: 16407829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Esophageal pepsin and proton pump synthesis in barrett's esophagus and esophageal adenocarcinoma.
    Samuels TL; Altman KW; Gould JC; Kindel T; Bosler M; MacKinnon A; Hagen CE; Johnston N
    Laryngoscope; 2019 Dec; 129(12):2687-2695. PubMed ID: 31046139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isoforms of RNF128 Regulate the Stability of Mutant P53 in Barrett's Esophageal Cells.
    Ray D; Ray P; Ferrer-Torres D; Wang Z; Nancarrow D; Yoon HW; San Martinho M; Hinton T; Owens S; Thomas D; Jiang H; Lawrence TS; Lin J; Lagisetty K; Chang AC; Beer DG
    Gastroenterology; 2020 Feb; 158(3):583-597.e1. PubMed ID: 31715145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular origins and molecular mechanisms of Barrett's esophagus and esophageal adenocarcinoma.
    Fang Y; Chen X; Bajpai M; Verma A; Das KM; Souza RF; Garman KS; Donohoe CL; O'Farrell NJ; Reynolds JV; Dvorak K
    Ann N Y Acad Sci; 2013 Oct; 1300():187-199. PubMed ID: 24117642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA methylation profiling in Barrett's esophagus and esophageal adenocarcinoma reveals unique methylation signatures and molecular subclasses.
    Kaz AM; Wong CJ; Luo Y; Virgin JB; Washington MK; Willis JE; Leidner RS; Chak A; Grady WM
    Epigenetics; 2011 Dec; 6(12):1403-12. PubMed ID: 22139570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-depth characterization of the Wnt-signaling/β-catenin pathway in an in vitro model of Barrett's sequence.
    Götzel K; Chemnitzer O; Maurer L; Dietrich A; Eichfeld U; Lyros O; Moulla Y; Niebisch S; Mehdorn M; Jansen-Winkeln B; Vieth M; Hoffmeister A; Gockel I; Thieme R
    BMC Gastroenterol; 2019 Mar; 19(1):38. PubMed ID: 30841855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypomethylation of noncoding DNA regions and overexpression of the long noncoding RNA, AFAP1-AS1, in Barrett's esophagus and esophageal adenocarcinoma.
    Wu W; Bhagat TD; Yang X; Song JH; Cheng Y; Agarwal R; Abraham JM; Ibrahim S; Bartenstein M; Hussain Z; Suzuki M; Yu Y; Chen W; Eng C; Greally J; Verma A; Meltzer SJ
    Gastroenterology; 2013 May; 144(5):956-966.e4. PubMed ID: 23333711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequent methylation of eyes absent 4 gene in Barrett's esophagus and esophageal adenocarcinoma.
    Zou H; Osborn NK; Harrington JJ; Klatt KK; Molina JR; Burgart LJ; Ahlquist DA
    Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):830-4. PubMed ID: 15824152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Evolution of Metaplasia to Adenocarcinoma in the Esophagus.
    Grady WM; Yu M
    Dig Dis Sci; 2018 Aug; 63(8):2059-2069. PubMed ID: 29766388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disintegrin and metalloproteinases (ADAMs) expression in gastroesophageal reflux disease and in esophageal adenocarcinoma.
    Kauttu T; Mustonen H; Vainionpää S; Krogerus L; Ilonen I; Räsänen J; Salo J; Puolakkainen P
    Clin Transl Oncol; 2017 Jan; 19(1):58-66. PubMed ID: 27026568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk.
    Schulmann K; Sterian A; Berki A; Yin J; Sato F; Xu Y; Olaru A; Wang S; Mori Y; Deacu E; Hamilton J; Kan T; Krasna MJ; Beer DG; Pepe MS; Abraham JM; Feng Z; Schmiegel W; Greenwald BD; Meltzer SJ
    Oncogene; 2005 Jun; 24(25):4138-48. PubMed ID: 15824739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Similarity of aberrant DNA methylation in Barrett's esophagus and esophageal adenocarcinoma.
    Smith E; De Young NJ; Pavey SJ; Hayward NK; Nancarrow DJ; Whiteman DC; Smithers BM; Ruszkiewicz AR; Clouston AD; Gotley DC; Devitt PG; Jamieson GG; Drew PA
    Mol Cancer; 2008 Oct; 7():75. PubMed ID: 18831746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temporal evolution in caveolin 1 methylation levels during human esophageal carcinogenesis.
    Jin Z; Wang L; Cao Z; Cheng Y; Gao Y; Feng X; Chen S; Yu H; Wu W; Zhao Z; Dong M; Zhang X; Liu J; Fan X; Mori Y; Meltzer SJ
    BMC Cancer; 2014 May; 14():345. PubMed ID: 24885118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of epigenetic alterations in the pathogenesis of Barrett's esophagus and esophageal adenocarcinoma.
    Agarwal A; Polineni R; Hussein Z; Vigoda I; Bhagat TD; Bhattacharyya S; Maitra A; Verma A
    Int J Clin Exp Pathol; 2012; 5(5):382-96. PubMed ID: 22808291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole genome expression array profiling highlights differences in mucosal defense genes in Barrett's esophagus and esophageal adenocarcinoma.
    Nancarrow DJ; Clouston AD; Smithers BM; Gotley DC; Drew PA; Watson DI; Tyagi S; Hayward NK; Whiteman DC; ;
    PLoS One; 2011; 6(7):e22513. PubMed ID: 21829465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma.
    Eads CA; Lord RV; Kurumboor SK; Wickramasinghe K; Skinner ML; Long TI; Peters JH; DeMeester TR; Danenberg KD; Danenberg PV; Laird PW; Skinner KA
    Cancer Res; 2000 Sep; 60(18):5021-6. PubMed ID: 11016622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subtypes of Barrett's oesophagus and oesophageal adenocarcinoma based on genome-wide methylation analysis.
    Yu M; Maden SK; Stachler M; Kaz AM; Ayers J; Guo Y; Carter KT; Willbanks A; Heinzerling TJ; O'Leary RM; Xu X; Bass A; Chandar AK; Chak A; Elliott R; Willis JE; Markowitz SD; Grady WM
    Gut; 2019 Mar; 68(3):389-399. PubMed ID: 29884612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.